ArticleHuman vaccines & immunotherapeutics2019
Reduction of influenza A(H3N2)-associated symptoms by influenza vaccination in school aged-children during the 2014-2015 winter season dominated by mismatched H3N2 viruses.
Article in Human vaccines & immunotherapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Article
- Influenza vaccine effectiveness among primary and secondary school students in Shenzhen during the 2023/24 influenza season.Emerging microbes & infections · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLittle is known about the vaccine effectiveness (VE) in attenuating the influenza-associated symptoms in children during the 2014-2015 influenza season in Beijing, China, in which there was a mismatch between the vaccine and circulating strain.
methodsThis study included 210 laboratory-confirmed influenza cases among children, who were enrolled in 2014, from November 1 to December 31. Standard demographic information and clinical symptoms were recorded. Influenza vaccination was confirmed via a vaccination registry. Univariate and multivariate analyses were used to estimate the odds of presenting with clinical symptoms among vaccinated and unvaccinated groups, adjusting for sex, age, area, BMI level, and chronic conditions.
resultsAmong the 210 laboratory-confirmed influenza cases, 170 (81.0%) presented with fever ≥38°C. The other most common symptoms were cough (78.1%), sore throat (46.7%), nasal congestion/rhinorrhea (38.6%), headache (34.8%), fatigue (24.8%) and myalgia/arthralgia (16.2%). Approximately 9.0% (19/210) exhibited nausea/vomiting, and 2.4% (5/210) exhibited diarrhea/abdominal pain. Respiratory complications occurred in 5.7% (12/210) of the confirmed influenza cases. In 210 laboratory-confirmed cases, univariate and multivariate conducted after adjusted for the aforementioned characteristics suggested that the odds of fever ≥ 38°C were significantly reduced in vaccinated children (odds ratio [OR]: 0.42, 95% CI: 0.19-0.93; P = 0.033).
conclusionsInfluenza vaccination may reduce the clinical symptoms of laboratory-confirmed influenza cases potentially even in the mismatching season.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.